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The myocyte enhancer factor-2 (MEF2) transcription factor plays a central role in the activation and maintenance of muscle gene
expression in fruit flies and vertebrates. The mechanism of action and downstream target genes of MEF2 have been defined in considerable
detail, but relatively little is known about the mechanisms that regulate MEF2 expression during muscle development. Here we demonstrate
that MEF2 maintains its own expression in all differentiated muscle cell types during late embryonic and larval development in Drosophila by
binding a conserved MEF2 site in a muscle-specific regulatory enhancer. Ectopic expression of Mef2 is sufficient to directly activate this
enhancer in some, but not all, non-muscle cells. Furthermore, activation of theMef2 enhancer normally in muscle cells and ectopically in non-
muscle cells is dependent upon the integrity of the MEF2 binding site. These findings suggest an evolutionarily conserved mechanism whereby
MEF2 can stabilize the muscle phenotype by sustaining its own expression through a myogenic autoregulatory loop.
D 2004 Elsevier Inc. All rights reserved.Keywords: Myocyte enhancer factor-2; Muscle; Mesoderm; Transcription; Autoregulation; Enhancer; Drosophila; Evolutionary conservationIntroduction
The process of muscle differentiation has been the subject
of intense study aimed at identifying the transcriptional
regulatory networks that are required for the specification,
differentiation, and maintenance of the muscle lineage.
Central to the formation of the musculature are members
of the Myocyte enhancer factor-2 (MEF2) family of MADS
(MCM1, Agamous, Deficiens, Serum response factor) do-
main transcription factors, which bind essential A/T-rich
sites in the control regions of most muscle structural genes.
There are four mammalian MEF2 factors—MEF2A, B, C,
and D—and a single MEF2 factor in Drosophila, which are
expressed in all muscle lineages during development
(reviewed in Black and Olson, 1998).
The central role of MEF2 in muscle development has
been demonstrated by genetic studies in mice and fruit flies.
Loss-of-function mutants for murine mef2c show a failure of
normal cardiac morphogenesis and differentiation with con-0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: rcripps@unm.edu (R.M. Cripps).comitant down-regulation of some cardiac muscle structural
genes (Q Lin et al., 1997), and dominant-negative isoforms
of MEF2 can inhibit myogenesis (Ornatsky et al., 1997).
Similarly, terminal differentiation of all muscle lineages is
abolished in Drosophila embryos lacking MEF2 (Bour et al.,
1995; Lilly et al., 1995; Ranganayakulu et al., 1995).
In vertebrate skeletal muscle, MEF2 cooperates with the
myogenic basic helix– loop–helix (bHLH) transcription
factors—MyoD, myogenin, Myf5, and MRF4—to activate
the muscle phenotype (Black et al., 1995; Li and Capetanaki,
1994; Molkentin et al., 1995; Naidu et al., 1995). In addition
to activating subordinate downstream genes in the skeletal
muscle differentiation pathway, MEF2 and myogenic bHLH
factors activate and maintain the expression of each other.
Expression of myogenic bHLH proteins in fibroblasts results
in up-regulation of MEF2 genes and conversion to the
muscle phenotype (Cserjesi and Olson, 1991; Lassar et al.,
1991; Martin et al., 1993). The promoters of the myogenin
and mrf4 genes also contain MEF2 binding sites that are
critical for muscle-specific expression (Black et al., 1995;
Cheng et al., 1993; Edmondson et al., 1992; Naidu et al.,
1995; Yee and Rigby, 1993). While MEF2 cannot activate
these promoters in non-muscle cells in the absence of
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ciated with E-boxes through which the myogenic bHLH
factors and MEF2 collaborate to regulate gene expression
(Molkentin et al., 1995; Ornatsky et al., 1997; Yu et al.,
1992).
Taken together, these studies have generated a robust
model to explain how myogenic factors initiate and main-
tain the muscle phenotype by both cross-regulation and
positive autoregulation. However, much remains to be
learned about the mechanisms that control expression of
MEF2 in different myogenic lineages. In Drosophila, we
have shown that the bHLH factor Twist is a direct and
essential activator of Mef2 expression in the skeletal muscle
lineage (Cripps et al., 1998). However, since twist expres-
sion levels decline during myogenesis (Baylies and Bate,
1996), other factors presumably act to maintain Mef2
transcription at later stages of development. Here, we
describe a muscle-specific enhancer that directs Mef2 tran-
scription in all differentiated somatic and visceral muscles of
the Drosophila embryo and in all differentiated muscles
during larval development. This enhancer is a direct target
of MEF2 and requires a single conserved MEF2 binding site
for activity. Our results demonstrate that maintenance of
MEF2 expression in mature muscle lineages results from a
direct positive feedback mechanism and suggest an evolu-
tionarily conserved mechanism for maintaining the muscle
phenotype.Materials and methods
DNA methods
The 12500/9112 construct was generated by purifi-
cation of a 3.5-kb EcoRI fragment from the cosmid CosD6,
which contains the entire Mef2 region (Lilly et al., 1995;
O’Brien et al., 1994). The 3.5-kb fragment was then cloned
directly into the promoter-lacZ transformation vector CHAB
(Thummel and Pirrotta, 1992). Mef2 enhancer constructs
within the 9117/8079 region were generated by PCR
using genomic DNA as a template, as was a construct
spanning 8159/5906. Primers used for each construct
were as follows: 9117/8079, IIB-1 (5V-GAATTCA-
GAATGTTTTTCATTC-3V) and Bin82 (5V-GCGGTCT-
GTGGGGAAGGAGC-3V); 9117/8467, IIB-1 and
Bin81 (5V-TTTTCCGATCTTTCTACACAA-3V); 8543/
8079, Bin71 (5V-TGTCCACCACCCCTTCCGCCC-3V)
and Bin82; 8371/8079, 2T-4 (5V-AAGGTGTGGGGAA-
GACTC-3 V) and Bin82; 8233/8079, 2T-5 (5 V-
CTGGCGATCGAGGCGAGC-3V) and Bin82; 8159/
5906, Bin72 (5V-ATTGCACAGACAGGCGAGAGG-3V)
and Bin100 (5V-GTTTCTGTTTCTGTATCTGT-3V). Muta-
genesis of enhancer sequences was performed as described
by Horton (1993) using the mutagenic primers MEFMUT+
(5V-GCACTTTGTCGGCGG TTAGCCCGAAATGCA-3V)
a n d M E FMU T ( 5 V- T T C G GG C TAA CGGCCGACAAAGTGC-3V); mutated sequences are underlined.
All PCR products were ligated into the pGEM-T Easy vector
(Promega Life Science, Madison, WI). Fragments were then
excised using appropriate restriction enzymes and inserted
into CHAB for generation of transgenic lines. Transgenic
lines carrying other enhancer regions fused to a lacZ reporter
were described previously (Cripps et al., 1999; Lilly et al.,
1995).
The pUAST/Mef2 plasmid was generated by cloning a
2.6-kb EcoRI fragment comprising the entire Mef2 coding
region (Lilly et al., 1995) into the pUAST vector (Brand and
Perrimon, 1993).
Fly stocks and crosses
Flies were maintained on Carpenter’s medium (Carpenter,
1950) at 25jC unless indicated. Transgenic lines were gen-
erated according to Rubin and Spradling (1982) using the
Delta2–3 helper plasmid (Robertson et al., 1988), and at least
three independent lines of each construct were tested for
enhancer activity. For ectopic expression ofMef2, lines were
generated which carried an X-linkedUAS-Mef2 insert as well
as an autosomal copy of either the wild-type or mutant Mef2
enhancer-lacZ constructs. For the wild-type enhancer, flies
had the genotypew P[w+UAS-Mef2]WT26A; P[w+9117/
8079Mef2-lacZ]82-8; for themutant enhancer, flies had the
genotype w P[w+ UAS-Mef2]WT26A; P[w+ 9117/
8079mutant Mef2-lacZ]82M-55. Virgin females from these
lines were crossed to males homozygous for the ectodermal
driver 69Bgal4 (Brand and Perrimon, 1993). Progeny em-
bryos of the following genotypes were represented at 100%:
w P[w+ UAS-Mef2]WT26A/+ or Y; P[w+ 9117/8079
Mef2-lacZ]82-8/69Bgal4; for the mutant enhancer: w P[w+
UAS-Mef2]WT26A/+ or Y; P[w+ 9117/8079mutant
Mef2-lacZ]82M-55/69Bgal4. Embryos were collected at
29jC for 16 h, and then processed for immunofluorescence
as indicated below.
Histochemistry and immunohistochemistry
Embryos aged 0–16 h were collected and subjected to
antibody staining essentially as described by Patel (1994).
Primary antibodies were mouse anti-h-galactosidase (Prom-
ega, 1:500) and rabbit anti-MEF2 (Lilly et al., 1995, 1:1000).
For colorimetric detection with diaminobenzidine (DAB),
the secondary antibody used was biotinylated goat anti-
mouse (1:1000) whose localization was detected using the
Vectastain Elite kit (Vector Laboratories, Burlingame, CA).
For fluorescent detection, the secondary antibodies were
Alexa-568 goat anti-rabbit and Alexa-488 goat anti-mouse
(Molecular Probes, Seattle, WA) each used at 1:2000. DAB-
stained embryos were cleared in 80% (v/v) glycerol,
mounted, and photographed on an Olympus BX51 micro-
scope with DIC optics using 35-mm slide film. Slides were
subsequently scanned to generate digital images. Fluores-
cently stained embryos were mounted in glycerol and sub-
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confocal laser scanning microscope with 488/568 nm exci-
tation in the dual channel mode (T1/T2A filter cubes,
BioRad, Hercules, CA).
To visualize h-galactosidase activity in larval skeletal and
visceral muscles, late third instar larvae were filleted and
fixed as described byMolina and Cripps (2001). Larvae were
then stained with an X-gal solution as described by Ash-
burner (1989). Stained samples were mounted and photo-
graphed using a microscope with a digital camera.
To study h-galactosidase accumulation in larval dorsal
vessels, samples were processed according to Molina and
Cripps (2001). Primary antibody used was mouse anti-h-
galactosidase (Promega, 1:10000) and secondary antibody
was Alexa-568 goat anti-mouse (1:2000). Secondary incu-
bations also contained Alexa-488 phalloidin (Molecular
Probes, diluted 1:500). Washed samples were mounted in
Slofade Anti-Fade mounting medium (Molecular Probes),
imaged by standard fluorescencemicroscopy, and captured as
digital images. All figures were assembled using Adobe
Photoshop.Fig. 1. Identification of skeletal muscle enhancers active during late embryonic and
muscles were tested for their ability to direct muscle-specific reporter gene express
location of genomic fragments tested; note that only the first two exons of Mef2 ar
white boxes indicate untranslated sequence; black boxes indicate translated sequen
be active in embryonic skeletal muscles at stage 16. Bottom: (A, B) enhancer activ
embryos (A), but barely detectable in L3 larvae (B); (C, D) enhancer activity of
Embryos are oriented with anterior to the left and dorsal uppermost, and images d
oriented with anterior to the left and dorsal midline at the top, and images show sta
white asterisks denote only a specific subset of the muscles to permit orientation.
Scale bar: 100 Am.DNA binding assays
Electrophoretic mobility shift assays were performed
essentially as described by Sambrook et al. (1989). Probe
DNA and unlabeled competitors were generated by annealing
complementary oligonucleotides to generate dsDNA mole-
cules with GG overhangs at each 5V end. Oligonucleotides for
wild-type were DM2+ (5V-GGTGTCTATATTTAGCCC-3V)
and DM2 (5V-GGGGGCTAAATATAGACA-3V); for mu-
tant competitor, DM2mut+ (5V-GGTGTCGGCCG TTA-
GCCC-3V) and DM2mut (5V-GGGGGCTAACGGCC
GACA-3V), mutated sequences underlined; and for mck
positive control, MCK+ (5 V-GGGCTCTAAAAA-
TAACCC-3V) and MCK (5V-GGGGGTTATTTTTA-
GAGC-3V). Annealed sequences were radioactively
labeledwith 32P-dCTP and Klenow enzyme (Roche Mo-
lecular Biochemicals, Indianapolis, IN), purified, and
diluted to 50000 cpm/Al. MEF2 protein was generated
from pcDNA-DMEF2 provided by Dr. Brian Black
(University of California, San Francisco) using the
Promega TNT coupled reticulocyte lysate kit (Promega
Biology 267 (2004) 536–547larval development. Enhancers active at the late embryonic stage in skeletal
ion in third instar larvae. Top: map of the Mef2 upstream region showing the
e indicated. R, EcoRI site; rightward arrow indicates transcription start site;
ce; red boxes indicate enhancer regions shown by Nguyen and Xu (1988) to
ity of the 12500/9112 region was strong in skeletal muscles of stage 16
the 9117/8079 region was strong in both embryos (C) and larvae (D).
epict immunohistochemical staining for h-galactosidase. Larval images are
ining for h-galactosidase activity. All skeletal muscles stain in panel D, and
White asterisks denote the DA1, DA2, and DA3 muscles (top to bottom).
Fig. 2. Deletion analysis of the 9117/8079 enhancer region. (A) Summary of enhancer-lacZ constructs tested and their activities in stage 16 embryos. The
location of a consensus MEF2 binding site is indicated. (B–D) Representative images of transgenic embryos carrying the indicated Mef2-lacZ constructs,
immunohistochemically stained with anti-h-galactosidase. Note that the full-length construct consistently showed the highest level of reporter gene expression,
but that sequences in the 3V half of the enhancer were sufficient for some muscle-specific activity (D). sm, skeletal muscles; scale bar, 100 Am.
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chemicals). Unprogrammed lysate was generated in the
same manner except lacking the plasmid DNA.Fig. 3. Expression profile of the 9117/8079 enhancer during embryonic and la
Mef2-lacZ construct showed dynamic reporter gene expression during embryonic
the longitudinal visceral muscles (A, vm), and was detected by stage 14 in skeletal
but no reporter gene expression was detected in the dorsal vessel (D, dv). In thir
visceral muscle fibers (E, lvm and tvm, respectively), and in the dorsal vessel (F)
Panel E is a histochemical stain for h-galactosidase activity. Panel G is an immuno
phalloidin stain of the sample in (F) to show the location of the dorsal vessel. All p
view; (D) dorsal view; (E) whole mount of larval gut; (F, G) ventral view of theBinding reactions contained polydI.dC (1 Ag), MEF2, or
unprogrammed lysate (3 Al), 1  buffer (Gossett et al.,
1989), competitor DNA (100  molar ratio), and water torval development. (A–D) Transgenic embryos carrying the 9117/8079
development. Expression was first detected at late stage 12 in precursors of
myoblasts (B, sm). By stage 16, activity was strong in visceral muscles (C),
d instar larvae, the enhancer was active in both longitudinal and transverse
. Panels A–D are immunohistochemical stains for h-galactosidase protein.
fluorescent detection of h-galactosidase protein, and panel H is a fluorescent
anels are oriented with anterior to the left. (A, B) Sagittal views; (C) ventral
dorsal midline of a filleted larva. Scale bar, 100 Am.
R.M. Cripps et al. / Developmental Biology 267 (2004) 536–547540bring the volume to 10 Al. Reactions were incubated at room
temperature for 20 min and then electrophoresed on a 3%
(w/v) non-denaturing polyacrylamide gel. The gel was dried
and exposed to autoradiography film overnight.Fig. 4. MEF2 protein binds to a conserved consensus sequence within the
9117/8079 enhancer. (A) Location of the conserved MEF2 binding site
in the 9117/8079 enhancer, and comparison of this sequence to similar
regions in the genomes of D. melanogaster (Dm), D. pseudoobscura (Dp),
and D. virilis (Dv). MEF2 consensus binding site is highlighted. (B)
Electrophoretic mobility shift assay to determine if MEF2 could bind to the
consensus site. Free probe had a high mobility in the gel in the presence of
lysate lacking MEF2 protein (Unp). A bound complex (MEF2) was formed
in the presence of MEF2 lysate, which was competed by a 100-fold excess of
nonradioactive wild-type sequence (WT) but not by a 100-fold excess of
nonradioactive mutant sequence (Mut). As a positive control, MEF2 was
shown to bind to the muscle creatine kinase (MCK) canonical MEF2 site.Results
Identification of a Mef2 enhancer active during larval
muscle development
Previous studies demonstrated that transcription of Mef2
in Drosophila embryos is regulated by a complex set of
independent enhancer elements dispersed throughout ap-
proximately 15 kb of upstream DNA (Cripps et al., 1998,
1999; Gajewski et al., 1997, 1998; Lilly et al., 1995; Nguyen
and Xu, 1998; Schulz et al., 1996). To understand howMef2
expression is maintained in fully differentiated muscle line-
ages, we analyzed this region for enhancers able to direct
expression of a lacZ transgene in larval muscles. While
there is a strong late embryonic skeletal muscle enhancer
contained within a 3.5-kb EcoRI fragment upstream of
Mef2 called III-F (Nguyen and Xu, 1998; Schulz et al.,
1996; Fig. 1A, construct 12500/9112), the 3.5-kb
fragment containing III-F displayed only weak enhancer
activity in the skeletal muscles of third instar larvae
(Fig. 1B).
By contrast, an adjacent 1-kb region (9117/8079)
contains a late skeletal muscle enhancer called II-E (Nguyen
and Xu, 1998; Fig. 1C). The 1-kb region maintained high
levels of enhancer activity in all of the skeletal muscles of
third instar larvae (Fig. 1D; the three dorsal acute muscles are
indicated with asterisks for orientation purposes). We also
tested additional enhancer constructs spanning the region
from 8079 to the EcoRI site at +521 for activity in larval
skeletal muscles; however, no activity was observed for any
additional enhancer fragment (data not shown). These data
indicate that the region between 9117 and 8079 contains
a powerful muscle-specific enhancer that functions as the
predominant regulator ofMef2 expression in somatic muscle
during late embryonic and larval life.
In order to localize sequences important for activity of the
9117/8079 enhancer, deletion constructs were tested for
enhancer activity in transgenic embryos (Fig. 2). Deletion of
approximately 400 bp of 3V sequence completely abolished
enhancer activity in the embryo (Figs. 2A, C; construct
9117/8467), whereas deletion of 574 bp from the 5V end
of the region resulted in a reduction in activity but not a
complete loss of enhancer function (Figs. 2A, D; construct
8543/8079). The latter construct was also active in larval
muscles (data not shown). Larger deletions from the 5V end
abolished all enhancer activity (Figs. 2A, E). These findings
indicated that muscle-specific activity of the enhancer could
be conferred by the 3V sequences, although the 5V region of the
complete enhancer is important for high levels of expression.
Therefore, subsequent analyses concentrated on the activityof the entire enhancer region (9117/8079) rather than on
deletion constructs with reduced activity.
Expression profile of the 9117/8079 enhancer
To determine the complete expression pattern of the
9117/8079 enhancer, transgenic flies harboring the lacZ
R.M. Cripps et al. / Developmental Biology 267 (2004) 536–547 541reporter controlled by this region were stained for h-
galactosidase at embryonic and larval stages. lacZ expres-
sion was first detected in the visceral muscle cells of late
stage 12 embryos (Fig. 3A), followed shortly by expres-
sion in skeletal myoblasts at stage 13 (Fig. 3B). By stage
16, the enhancer showed strong activity in all skeletal
(Nguyen and Xu, 1998; Fig. 1C) and visceral muscles
(Fig. 3C). However, during embryogenesis, the enhancer
showed no detectable activity in the dorsal vessel (Fig.
3D). To determine if this enhancer was also active in
tissues other than skeletal muscle later in development, the
alimentary canal was dissected out of third instar larvae,
fixed, and stained with X-gal. Strong staining was ob-
served in both the longitudinal and transverse muscle
fibers of the gut mesoderm (Fig. 3E). h-Galactosidase
was also detected in the dorsal vessel of filleted third
instar larvae (Fig. 3F).Fig. 5. The MEF2 binding site is required for enhancer activity. Activity of the 9
(A, F) and L3 larval muscles was tested. In all cases, the strong activity of the wild
the 9117/8079 enhancer. (B, G) Skeletal muscles stained as in Fig. 1; (C, H) v
counterstained as in Fig. 3. sm, skeletal muscle; vm, visceral muscle; lvm, longi
skeletal muscle fibers. Orientations are as indicated in earlier figures. Scale bar, 1These findings indicate that the 9117/8079 enhancer
displays a strikingly broad spectrum of activity in all of the
differentiated muscle lineages of the larva. It is also inter-
esting that the onset of activity of this enhancer matches the
onset of terminal muscle differentiation in each lineage:
visceral muscle cells activate markers of terminal differen-
tiation earliest during embryogenesis, followed by skeletal
muscle cells, and finally by cells of the dorsal vessel
(Herranz et al., 2004; Kelly et al., 2002; Zhang and
Bernstein, 2001).
Identification of a conserved MEF2 binding site in the
9117/8079 enhancer
To begin to understand the molecular basis for the activity
of the9117/8079 enhancer, we analyzed the sequence for
binding sites of known muscle regulatory factors. In the 3V117/8079 wild-type (A–D) or mutant (F–I) enhancer in stage 16 embryos
-type enhancer was ablated upon mutation of the MEF2 site in the context of
isceral muscles stained as in Fig. 3; (D, E, I, J) cardiac muscle stained and
tudinal visceral muscle, dv, dorsal vessel. Asterisks denote DA1, 2, and 3
00 Am.
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tional activity, we identified a 10-bp sequence located at
8209/8200 that perfectly matched the consensus binding
site for MEF2 proteins (Andres et al., 1995; Fig. 4A).
Examination of the upstream regions of the Mef2 genes of
two related Drosophila species, D. pseudoobscura (Mega-
BLAST at URL: http://www.ncbi.nih.gov/blast/mmtrace.
html) and D. virilis (Cripps et al., 1999), revealed that the
MEF2 consensus binding sequence was also conserved for
these genes, suggesting an important function.
To determine if MEF2 protein was capable of interacting
with the putative MEF2 site, an electrophoretic mobility shift
assay was performed using a radioactively labeled double-
stranded oligonucleotide corresponding to the putative
MEF2 site plus five flanking nucleotides. MEF2 protein
generated in vitro bound strongly to the radioactive probe
DNA sequence, and binding was competed by an identical
unlabeled oligonucleotide but not by an oligonucleotide in
which the MEF2 site had been mutated (Fig. 4B). TheFig. 6. The 9117/8079 enhancer can be activated by ectopic MEF2 in vivo. Em
to ectopic Mef2 expression and tested for the activation of Mef2 and reporter g
Accumulation of MEF2 protein (red) in the ectoderm and amnioserosa of transg
protein (green) occurred in embryos carrying the wild-type enhancer, but not in th
cells of the amnioserosa that activated the reporter gene in response to MEF2 p
indicate the nucleus of an amnioserosa cell. All panels show dorsal views with acanonical MEF2 site from the mck gene (Cserjesi et al.,
1994) was included as a positive control. These findings
suggested that the 9117/8079 Mef2 enhancer might be
activated, at least in part, by the product of the Mef2 gene
itself.
The MEF2 binding site is required for enhancer activity in
all muscle lineages
The data presented in Fig. 2 suggested that the conserved
MEF2 site was important for muscle-specific expression,
since its deletion eliminated enhancer activity. However,
the MEF2 site and adjacent sequences are not sufficient for
activity since neither the 8371/8079 nor the 8233/
8079 regions, which contain this site, showed activity
(see Fig. 2).
Therefore, to determine the functional significance of the
MEF2 binding site, the sequence was mutated in the context
of the 9117/8079 enhancer to the same sequence used asbryos carrying wild-type or mutant 9117/8079 enhancers were subjected
ene expression via immunofluorescence and confocal microscopy. (A, D)
enic animals; (B, E) accumulation in the same embryos of h-galactosidase
ose carrying the mutant enhancer. (C, F) Merge of previous images shows
rotein. White dashed line delimits the amnioserosa; white arrows in A–C
nterior to the left. Scale bar, 100 Am.
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wild-type enhancer was active strongly in all differentiated
muscle lineages (Figs. 5A–D), the mutant enhancer showed
no activity at any stage of embryogenesis or larval develop-
ment (Figs. 5F–I).
Ectopically expressed Mef2 can ectopically activate the
9117/8079 enhancer
To determine if the 9117/8079 enhancer could be
activated in non-muscle cells by MEF2, we used the Gal4-
UAS system to ectopically express Mef2 by using the
ectodermal driver 69B-gal4 and an X-linked UAS-Mef2
construct (see Materials and methods for details). Flies were
stained for the co-expression of ectopic MEF2 protein and h-
galactosidase from the enhancer-lacZ reporter.
MEF2 was expressed at a high level in the ectoderm and
amnioserosa of w P[w+ UAS-Mef2]WT26A/+ or Y; P[w+Fig. 7. Expression of the 9117/8079 enhancer is restricted to differentiated skel
wing imaginal discs from 9117/8079 Mef2-lacZ transgenic lines accumulated M
protein in those cells (B). (C, D) Similarly, cells of the mushroom body of the larv
bar, 100 Am.9117/8079 Mef2-lacZ]82-8/69Bgal4 embryos, as visual-
ized by confocal microscopy (Fig. 6A). The same animals
showed strong expression of lacZ in ectopic locations (Figs.
6B, C), although only in a subset of the cells of the
amnioserosa and no cells in the ectoderm. By contrast, the
enhancer with the MEF2 site mutation was not activated by
ectopic MEF2 expression in w P[w+ UAS-Mef2]WT26A/+
or Y; P[w+ 9117/8079mutant Mef2-lacZ]82M-55/
69Bgal4 embryos (Figs. 6D–F). These findings demonstrat-
ed that MEF2 could activate the autoregulatory enhancer in
non-muscle cells to varying degrees and suggested that the
amnioserosa is a more permissive environment for ectopic
activation of the enhancer than the ectoderm.
To extend these observations, we looked at enhancer
activity in additional cells that express Mef2 during the
larval stage. The wing imaginal discs express high levels of
MEF2 at the end of the third larval instar (Ranganayakulu et
al., 1995; Cripps et al., 1998; Fig. 7A); however, theetal muscles of third instar larvae. (A, B) Immunofluorescence revealed that
EF2 in the adepithelial cells (A, ac) but did not accumulate h-galactosidase
a accumulated MEF2 (C, mb) but did not accumulate h-galactosidase. Scale
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this stage of development (Fig. 7B). These results are
consistent with our earlier observation that an enhancer
closer to the Mef2 promoter is solely responsible for Mef2
activation in the wing discs (Cripps et al., 1998). The
autoregulatory enhancer was also inactive in the mushroom
body cells of the brain, which express Mef2 in late third
instar larvae (Schulz et al., 1996; Figs. 7C, D). Thus, the
enhancer is not a simple reporter of Mef2 expression but is
specifically active in a subset of MEF2-positive cells.Discussion
Cellular phenotypes can be stabilized by transcriptional
feedback mechanisms as well as by chemical and structural
modifications of the DNA (reviewed in Dillon and Grosveld,
1994), which maintain expression of cell-specific regulatory
and structural genes. Examples of positive autoregulation of
transcription are found in muscle development in vertebrates
(reviewed in Yun and Wold, 1996; Ludolph and Konieczny,
1995) and in proneural gene expression in Drosophila
(Helms et al., 2000; Sun et al., 1998). Furthermore, recent
genome-scale analyses of gene regulatory networks reveal
that positive autoregulation is a common maintenance mech-
anism for the expression of regulatory genes (Davidson et al.,
2002).
Positive autoregulation by MEF2
The results of the study presented here demonstrate that
MEF2 directly and positively autoregulates transcription
during the late stages of muscle development in Drosophila.
We show that the autoregulatory enhancer is capable of
providing readout for the presence of MEF2: the enhancer is
not expressed in non-muscle cells in the embryo, it can be
activated by ectopic MEF2, and the activity of the enhancer
is critically dependent upon a MEF2 binding site. Together
these results provide compelling evidence of a positive
autoregulatory role for Mef2 in differentiated muscles.
Since Mef2 is essential for muscle differentiation in
Drosophila via direct activation of muscle structural genes
(Lin et al., 1996; Ranganayakulu et al., 1995; Kelly et al.,
2002; Arredondo et al., 2001), it is likely that sustainedMef2
expression is required for muscle maintenance and growth
during the larval stage. Furthermore, since the Mef2 auto-
regulatory enhancer is active relatively late in embryonic
development and remains active throughout the larval stage,
the enhancer is likely to account, at least in part, for
maintenance of the muscle phenotype via sustained activa-
tion of Mef2.
The cells in which the 9117/8079 enhancer is active
share the common feature of being late in the differentiation
pathway. The temporal pattern of activation of the enhancer
(visceral, then skeletal, then cardiac muscles) matches the
generally accepted order in which these muscle lineagesbegin to express markers of terminal muscle differentiation
(Herranz et al., 2004; Kelly et al., 2002; Zhang and Bern-
stein, 2001). By contrast, the early mesoderm, despite
expressing Mef2, does not show enhancer activity; and the
adepithelial cells of the wing disc are also myoblasts that
have yet to initiate the differentiation program (Fernandes et
al., 1991). Therefore, one possibility is that a MEF2 cofactor
critical for activity of the autoregulatory enhancer is induced
specifically in differentiating cells.
An alternative possibility is that the MEF2 protein in the
early mesoderm, in the adepithelial cells and in the mush-
room body, is rendered transcriptionally inactive. It is
known that in vertebrates, MEF2 function can be post-
translationally regulated by class II histone deacetylases
(Lemercier et al., 2000; Lu et al., 2000; Miska et al.,
1999). Since MEF2 is present in the early mesoderm of
Drosophila embryos from stage 6 (Bour et al., 1995; Lilly et
al., 1995), yet the earliest known targets of MEF2 are not
activated until stages 10–11 (Kelly et al., 2002; Taylor,
2000), one possibility is that Drosophila MEF2 does not
acquire transcriptional activity until the onset of differenti-
ation. Thus, the inability of MEF2 to activate the 9117/
8079 enhancer in the early mesoderm, the adepithelial
cells, or the mushroom body, and the relative ineffectiveness
of ectopic MEF2 in activating the enhancer might reflect
cellular environments repressive to MEF2-mediated differ-
entiation. The Drosophila class II histone deacetylase
encoded by CG1770 is expressed broadly at low levels in
the embryo (Zeremski et al., 2003) and thus could carry out
this function early. Whether this gene is also expressed
during the third larval instar in imaginal discs or brain
remains to be determined. However, it should also be noted
that the MEF2 site alone is not sufficient for enhancer
activity (see Fig. 2); therefore, the full activation of this
enhancer might arise from the effects of both additional
trans-acting factors as well as modulation of MEF2 activity.
Requirement for factors in addition to MEF2 on the
autoregulatory enhancer
The ectopic expression assays confirm that MEF2 is
capable of activating the autoregulatory enhancer outside
muscle cell lineages, although it is unclear why the enhancer
is not activated in all cells expressing ectopic MEF2. This
finding may result from subtle cell-to-cell variations in the
level of MEF2 accumulation from the UAS transgene, such
that the enhancer is only activated above a certain threshold
of MEF2 concentration. The level of this threshold may
depend upon the ability of MEF2 to overcome either effects
of repressive factors, or alternatively the absence of positive
co-regulators that are restricted to muscle lineages.
In vertebrates, MEF2 factors collaborate with tissue-
restricted cofactors to activate target gene expression (Mol-
kentin et al., 1995), and there is significant evidence that this
is also the case in Drosophila (SC Lin et al., 1997). It is
therefore likely that MEF2 collaborates with additional
R.M. Cripps et al. / Developmental Biology 267 (2004) 536–547 545factors on the autoregulatory enhancer, and it is possible that
such factors could also be distinct in each muscle type. Our
deletion analyses indicating that sequences in the 5V half of
the 9117/8079 enhancer are required for full enhancer
activity are consistent with this hypothesis. However, the
identity of these additional factors remains unknown since
no other known binding sites for muscle-specific regulators
reside in this location. Furthermore, an E-box located close
to the MEF2 site, while strongly conserved, is not required
for enhancer activity.
Additional support for the conclusion that MEF2 alone is
insufficient for enhancer activation comes from the fact that
there are cells that express Mef2 in which the 9117/8079
enhancer is not active. These include the early mesoderm of
the embryo (Bour et al., 1995; Lilly et al., 1995), the
adepithelial cells of the wing imaginal disc (Cripps et al.,
1998), and a subset of cells of the mushroom body of the
brain (Schulz et al., 1996). Thus, the 9117/8079 en-
hancer is not simply an indicator of MEF2 presence in a cell
but is specific to a particular subset of the mesoderm.
Possible evolutionary conservation of muscle regulatory
pathways
There is significant evolutionary conservation in the
transcriptional pathways for normal development, and this
conservation extends to the regulatory networks used to
control myogenesis. Gain-of-function assays have demon-
strated that myogenic bHLH factors can activate verte-
brate mef2 gene transcription (Cserjesi and Olson, 1991;
Lassar et al., 1991; Martin et al., 1993); this is also the
case in Drosophila, where the bHLH factor Twist can
activate Mef2 expression at high levels (Taylor et al.,
1995). More recent studies of vertebrate mef2c have
determined that this activation occurs via a skeletal
muscle enhancer that is strongly responsive to myogenic
bHLH gene activation (Dodou et al., 2003; Wang et al.,
2001); and this is paralleled in Drosophila by the
observation that the bHLH factor Twist is a direct and
positive regulator of Mef2 expression (Cripps et al.,
1998). In addition, the mef2c enhancer contains an AT-
rich sequence essential for activation in vivo (Dodou et
al., 2003; Wang et al., 2001) and which has been shown
to bind to MEF2 protein (Wang et al., 2001). This result
is paralleled by the data presented here demonstrating
that Drosophila Mef2 undergoes positive autoregulation
and reinforces the notion that cellular specification and
differentiation pathways have been strongly conserved
over large periods of evolutionary time. Thus, the autor-
egulatory loop uncovered in this study could be a
component of an evolutionarily conserved mechanism
by which muscle cells maintain the muscle phenotype.
However, since positive autoregulation is a common
occurrence among regulatory genes, it is also possible
that Mef2 autoregulation evolved independently in diverse
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